ZURICH (Reuters) - Novartis plans to spin off its Alcon eye care business to shareholders and repurchase up to $5 billion in shares, as Chief Executive Vas Narasimhan refocuses the Swiss firm on prescription drugs.
Reuters: Business News, Reuters: Business
Fri, 06/29/2018 - 1:14am
ZURICH (Reuters) - Novartis plans to spin off its Alcon eye care business to shareholders and repurchase up to $5 billion in shares, as Chief Executive Vas Narasimhan refocuses the Swiss firm on prescription drugs.